Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
“2023 was a banner year for Collegium Pharmaceutical.
- “2023 was a banner year for Collegium Pharmaceutical.
- We delivered record financial results, achieved our operational objectives and delivered value to shareholders through our share repurchase program,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium.
- We are committed to achieving our financial guidance and deploying capital to create value for our shareholders.”
“In 2023, we achieved our financial guidance, delivering record revenue, adjusted EBITDA and free cash flow. - In 2023, returned $75.0 million in capital to shareholders through accelerated share repurchase programs, including $25.0 million repurchased at an average price per share of $27.09 in the quarter ended December 31, 2023.